Espinosa Neuroscience Institute

12/17/2025

🚨 Retatrutide achieved an average weight loss of 28.7% - Anti-Obesity Therapy Is Not Incremental Anymore — It’s Transformational

Three days ago, results from the TRIUMPH-4 trial were released.

Patients with obesity and knee osteoarthritis treated with retatrutide 12 mg achieved an average weight loss of 28.7% at 68 weeks.

Let that sink in.

🔹 This level of weight loss approaches bariatric surgery outcomes
🔹 For knee osteoarthritis, this may translate into less pain, improved mobility, and delayed joint replacement
🔹 Highlights the power of triple-agonist therapy (GLP-1 / GIP / Glucagon) over prior generations

We are clearly entering a new era where medical therapy may rival surgical intervention for obesity-related disease.

📉 Obesity is no longer “lifestyle only.”
📈 The science has caught up.


Patricio Sebastian Espinosa

12/16/2025

GLP-1–Based Weight Loss: The Evolution of Obesity Treatment

📉 Average Weight Reduction in Obesity Trials

• Semaglutide (GLP-1): ~15%
• Tirzepatide (GLP-1 + GIP): ~22.5%
• Retatrutide (GLP-1 + GIP + Glucagon): ~28.7%

This is not incremental progress — this is therapeutic evolution.

As GLP-1–based therapies advance from single → dual → triple agonists, outcomes are now approaching surgical-level weight loss for many patients.

Obesity is a chronic disease, and GLP-1 science is reshaping how we treat it.

—
Espinosa Neuroscience Institute & Wellness Center


Patricio Sebastian Espinosa
International Neurology Foundation

12/14/2025

🧠 Botox for Migraine: What the Science Shows

PRECLUDE Study Takeaway

The PRECLUDE trial demonstrated that onabotulinumtoxinA (Botox®) does NOT provide meaningful benefit for episodic migraine
➡️ defined as < 15 headache days per month

🔍 Key Point
• Botox is effective for chronic migraine (≥15 headache days/month)
• Botox is NOT supported for episodic migraine based on high-quality clinical data

📊 Why this matters
Using the right treatment for the right patient:
• Improves outcomes
• Avoids unnecessary procedures
• Ensures evidence-based care

At Espinosa Neuroscience Institute & Wellness Center, we tailor migraine treatment using science—not trends.

📍 Chronic migraine? Botox may help
📍 Episodic migraine? Other therapies are more effective



Patricio Sebastian Espinosa

12/14/2025

🔬 Alzheimer’s Drug Update: Not Ready for Prime Time

GLP-1 therapy for Alzheimer’s disease just faced a major setback.

Novo Nordisk announced that the large Phase 3 EVOKE & EVOKE+ trials of oral semaglutide (Rybelsus) in early-stage Alzheimer’s disease failed to slow memory or cognitive decline compared with placebo.

✔️ The drug was safe
✔️ Some biomarkers improved (including tau-related markers)
❌ But clinical outcomes did not improve

Because the trials missed their primary endpoints, further development for Alzheimer’s has been discontinued.

This is an important reminder:
Biomarker changes ≠ meaningful clinical benefit.
Until therapies clearly slow cognitive decline, they are not ready for prime time.

We must continue to demand rigorous, outcome-driven science for our patients and families affected by Alzheimer’s disease.

— Patricio S. Espinosa, MD
Neurology | Neurodegenerative Disease


Patricio Sebastian Espinosa
International Neurology Foundation

12/14/2025

🧠 Anti-Tau Therapy: Not Ready for Prime Time

The Phase 2 Auτonomy study evaluating an anti-tau monoclonal antibody in early Alzheimer’s disease was recently discontinued after failing to demonstrate a statistically significant slowing of clinical decline.

While disappointing, this outcome reinforces an important reality in Alzheimer’s research: tau-targeted therapies are not yet ready for clinical prime time.

Despite a compelling biological rationale and sophisticated biomarker-guided trial designs, translating tau modulation into meaningful clinical benefit remains elusive. For now, anti-tau approaches are unlikely to become effective disease-modifying treatments in the near future.

Science moves forward through rigorous testing—successes and failures alike. Each study helps refine our understanding of this extraordinarily complex disease.

11/27/2025

11/27/2025

🍁 Happy Thanksgiving from the Espinosa Neuroscience Institute 🍁

Today, we pause with gratitude for each of our patients, families, and caregivers who place their trust in us every day.
Your strength, resilience, and partnership inspire our entire team, and we are honored to be part of your care and your journey.

As we celebrate this season of thanks, we want you to know how deeply we appreciate you.
From our ENI family to yours — we wish you a day filled with peace, connection, and gratitude.

Thank you for being part of the ENI community.
Warm Thanksgiving wishes to you and your loved ones. 🧡🦃

— Espinosa Neuroscience Institute
Patricio Sebastian Espinosa

11/05/2025

Thank you Allegiance Home Health & Rehab for inviting me to speak at Royal Palm Yacht Club. The Espinosa Neuroscience Institute is delighted to support the community with cutting-edge information in neurosciences.

Allegiance Home Health & Rehab Espinosa Neuroscience Institute Patricio Sebastian Espinosa International Neurology Foundation

11/03/2025

**** Inportant News ****

The “Ozempic effect” is finally showing up in national data.
For the first time in decades, U.S. obesity rates are declining. Gallup’s 2025 survey shows a drop from 39.9% to 37%, marking the first meaningful reversal in a 60-year upward trend.

GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound are reshaping metabolic health and offering real hope to millions of people who have struggled with weight despite diet, exercise, and lifestyle changes.

This is one of the most important public-health shifts we’ve seen in years — and we’re seeing the impact every day in our own patients.

✅ These amazing treatments are available at the Espinosa Neuroscience Institute and Wellness Center.
If you want to learn more about medical weight-loss options, we’re here to help.

Patricio Sebastian Espinosa
International Neurology Foundation
Espinosa Neuroscience Institute

10/31/2025

🎃 Happy Halloween from the entire team at Espinosa Neuroscience Institute! 🧠👻

Whether we’re decoding brain mysteries or channeling our inner Slash, Ghostface, or wicked witch, we’re always ready to bring the spooky science vibes!

Wishing you a night full of treats, thrills, and zero brain freezes! 🕷️🧪



Patricio Sebastian Espinosa
Espinosa Neuroscience Institute
International Neurology Foundation